Can the second-generation tyrosine kinase inhibitors be as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients?.
10.3760/cma.j.issn.0253-2727.2014.02.006
- Author:
Ping ZOU
1
Author Information
1. Department of Hematology, Union Hospital,Tongji Medical College, Huazhong University of Scinence and Technology, Wuhan 430022, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Leukemia, Myeloid, Chronic-Phase;
drug therapy;
Protein-Tyrosine Kinases;
antagonists & inhibitors
- From:
Chinese Journal of Hematology
2014;35(2):99-100
- CountryChina
- Language:Chinese
